Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-CD3 antibody MacroGenics Inc.

William M Brown1

  • 1Paddock Laboratories Inc, 3940 Quebec Avenue North, Minneapolis, MN 55427, USA. wbrown@paddocklabs.com

Current Opinion in Investigational Drugs (London, England : 2000)
|April 22, 2006
PubMed
Summary

A novel antibody, hOKT3gamma1 (Ala-Ala), shows potential for treating type 1 diabetes and autoimmune diseases. Clinical trials are underway to evaluate its efficacy and safety in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcatheter Aortic Valve Replacement in Patient With Extensive Aortic Dissection: Role of "Balloon Flossing".

Journal of the Society for Cardiovascular Angiography & Interventions·2025
Same author

Impact of low testing numbers on chronic wasting disease apparent prevalence.

Prion·2025
Same author

The Value and Challenges of an Ambulatory Intermediate Care Clinic: A Mixed-Methods Analysis.

The Journal of ambulatory care management·2025
Same author

Improved performance of nucleic acid-based assays for genetically diverse norovirus surveillance.

Applied and environmental microbiology·2023
Same author

Version or High Forceps, Which and When?

Buffalo medical journal·2023
Same author

The Impact of Variation in the Toll-like Receptor 3 Gene on Epizootic Hemorrhagic Disease in Illinois Wild White-Tailed Deer (<i>Odocoileus virginianus</i>).

Genes·2023

Area of Science:

  • Immunology
  • Pharmacology
  • Clinical Medicine

Background:

  • hOKT3gamma1 (Ala-Ala) is a non-FcR-binding anti-CD3 monoclonal antibody.
  • Originally developed at Columbia University, it is being advanced by MacroGenics.

Purpose of the Study:

  • To evaluate the potential of hOKT3gamma1 (Ala-Ala) in treating type 1 diabetes and autoimmune diseases.
  • To assess the drug's safety and efficacy in ongoing clinical trials.

Main Methods:

  • Phase I/II clinical trials in diabetic patients have been completed.
  • Phase II clinical trials initiated for psoriatic arthritis and new-onset diabetes.

Main Results:

  • Completed Phase I/II trials in diabetic patients.
  • Initiated Phase II trials in psoriatic arthritis and new-onset diabetes.

Conclusions:

  • hOKT3gamma1 (Ala-Ala) is under investigation for type 1 diabetes and autoimmune disease treatment.
  • MacroGenics is seeking a strategic partner to further develop this therapeutic candidate.

Related Experiment Videos